What a headline! Brought me back to AP Bio. Also - a very accurate takeaway from this year's AACR. BioCentury

J&J’s William Hait highlighting the burden on pharma to launch products : 40 phase 1 ➡️ 3 BLAs! Hence $2B+ per drug launched. #AACR24 “Path to Entrepreneurship” session

Great writeup on DACs from BioCentury! Lot of potential combinations of targets and payloads - looking forward to seeing the field evolve 🚀

biocentury.com/article/651882…

Company News: Nobel laureate Carolyn Bertozzi on the launch of Firefly Bio and the science of degrader antibody conjugates.

Full video: biotechtv.com/post/firefly-b…

Excited to announce our newest portfolio company - Firefly Bio! Debuting with $94M, Firefly is pioneering degrader-antibody conjugates as an evolution to ADCs. MPM co-led the Series A financing with Versant Ventures, alongside Decheng and Lilly

fireflybiologics.com/press-release-…

28% reduction in rate of heart attacks and 19% reduction in all-cause death for patients in this trial taking wegovy 🤯

MPM BioImpact is pleased to participate in the Series A financing of AstronauTx to develop novel treatments for Alzheimer’s disease and other neurodegenerative disorders. Read the press release: astronautx.bio/astronautx-clo…

Nice article in BioCentury on circular RNA - featuring our own Orna Therapeutics!

biocentury.com/article/648805…

It depends on your definition of bioengineering. Protein engineering, syn bio, gene editing are all making major breakthroughs.

Using engineering principles to predict/model biology is limited by the quality of the measurements we can take and translatability of the assays

Congrats to Crossbow Therapeutics on the launch and $80M Series A! Inspired by the success of KIMMTRAK, Crossbow was founded by MPM BioImpact Capital to pioneer TCR-mimetic antibodies to tackle intracellular tumor antigens!

biospace.com/article/releas…

Thanks to MassBio for having me in a panel this morning discussing the investment climate and it's impact on biotech decisionmaking!

VOD: youtube.com/watch?v=GE3Xc5…

Grateful to see this (finally) come out! Hope Ram can find peace & move forward

statnews.com/2023/06/14/ram…

Scientific dishonesty is tricky to untangle, but ultimately the responsibility lies with management, especially CEO & CSO. Culture emanates from the top down and pressure to produce results creates conflicting incentives.

Sprint at the killer experiments, don't avoid them

😮

statnews.com/2023/06/12/lar…

Thank you to Brian Goodman and Devin Quinlan at MPM BioImpact Capital for hosting the Harvard Biotech Club Pitch Deck Creation Workshop of the Engage series! Students learned the essential elements of a compelling pitch deck and presented their business ideas to MPM employees for feedback.

Congrats to David and the Elevate team!

Announcing ReNAgade Therapeutics! An MPM-founded company focused on all things RNA, with over $300M in capital! I am grateful to have played a small part, but want to congratulate the rest of the team on the awesome build and launch!

Congratulations to our portfolio co ReNAgade Therapeutics: $300M+ Series A financing to dramatically transcend boundaries of RNA medicine. Financing led by MPM BioImpact & F2 Ventures. ReNAgade JV with MPM BioImpact-founded @Ornatx provides early validation of its technologies. #biotech